{"id":6974,"date":"2025-12-10T15:48:56","date_gmt":"2025-12-10T15:48:56","guid":{"rendered":"https:\/\/bristishpharmacy.co.uk\/?post_type=product&#038;p=6974"},"modified":"2026-09-16T10:12:44","modified_gmt":"2026-09-16T10:12:44","slug":"wegovy-2-4mg","status":"publish","type":"product","link":"https:\/\/bristishpharmacy.co.uk\/nl\/shop\/wegovy-2-4mg\/","title":{"rendered":"Wegovy 2,4 mg"},"content":{"rendered":"<h1>\u00a0<\/h1>\n<div class=\"container\">\n<div id=\"model-response-message-contentr_53b9e12d9ad98550\" class=\"markdown markdown-main-panel md-content enable-luminous-fast-follows enable-updated-hr-color stronger tutor-markdown-rendering\" dir=\"ltr\" aria-live=\"polite\">\n<h3 data-path-to-node=\"3\">Clinical Monograph: Wegovy 2.4 mg (Semaglutide)<\/h3>\n<div class=\"attachment-container search-images\">\n<div class=\"image-container spark-licensed-center hide-from-message-actions ng-star-inserted\" data-full-size-image-uri=\"https:\/\/cdn.prod.website-files.com\/65be9c17b97a9e17808c8a35\/6939b297b3b66e310299ebe0_688bfaba67c87623d7a6d54f_Click%2520Counting%2520Wegovy%25202.4%2520mg%2520pen.webp\">\n<div class=\"overlay-container hero-overlay-container ng-star-inserted\"><button class=\"image-button ng-star-inserted\"><img fetchpriority=\"high\" decoding=\"async\" class=\"spark-licensed-landscape hero-image loaded\" src=\"https:\/\/encrypted-tbn0.gstatic.com\/images?q=tbn:ANd9GcQMbUPhnPi6UsdjKXlHI3YQsMuwjLNRBhZZmSGQ37aXOfsnMlq-pc9r2Uw&amp;s=10\" alt=\"Wegovy 2.4 mg single-dose pre-filled injection pen, AI generated\" width=\"387\" height=\"258\" \/><\/button><\/p>\n<div class=\"hero-caption-row ng-star-inserted\">\n<div class=\"caption gds-extended-caption hero-caption ng-star-inserted\" aria-hidden=\"true\">Wegovy 2.4 mg single-dose pre-filled injection pen. <span class=\"ng-star-inserted\">Source: Well Revolution<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2 data-path-to-node=\"5\">1. Classification and Chemical Overview<\/h2>\n<p data-path-to-node=\"6\">Semaglutide is a synthetic human GLP-1 receptor agonist sharing 94% sequence homology with native human GLP-1. It is chemically modified via an amino acid substitution at position 8 (alanine to <span class=\"math-inline\" data-math=\"\\alpha\" data-index-in-node=\"194\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord mathnormal\">\u03b1<\/span><\/span><\/span><\/span><\/span>-aminobutyric acid) to impart resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, alongside an attached <span class=\"math-inline\" data-math=\"C_{18}\" data-index-in-node=\"307\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\"><span class=\"mord mathnormal\">C<\/span><span class=\"msupsub\"><span class=\"vlist-t vlist-t2\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"sizing reset-size6 size3 mtight\"><span class=\"mord mtight\">18<\/span><\/span><\/span><\/span><span class=\"vlist-s\">\u200b<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span> fatty diacid side chain at position 26 via a spacer to facilitate reversible albumin binding. Under the Anatomical Therapeutic Chemical (ATC) system, semaglutide is classified under A10BJ06.<\/p>\n<p data-path-to-node=\"7\">Wegovy 2.4 mg represents the highest approved therapeutic maintenance strength. Depending on regional regulatory presentations, it is supplied either as single-dose pre-filled autoinjector pens delivering a 0.75 mL volume (<span class=\"math-inline\" data-math=\"3.2\\text{ mg\/mL}\" data-index-in-node=\"223\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\">3.2<\/span><span class=\"mord text\"><span class=\"mord\">\u00a0mg\/mL<\/span><\/span><\/span><\/span><\/span><\/span>) or multi-dose FlexTouch pens. In the UK, EU, and US, Wegovy is classified as a Prescription Only Medicine (POM).<\/p>\n<h2 data-path-to-node=\"8\">2. Mechanism of Action and Pharmacodynamics<\/h2>\n<p data-path-to-node=\"9\">Semaglutide functions as a selective GLP-1 receptor agonist that binds to and activates central and peripheral GLP-1 receptors:<\/p>\n<ul data-path-to-node=\"10\">\n<li>\n<p data-path-to-node=\"10,0,0\"><b data-path-to-node=\"10,0,0\" data-index-in-node=\"0\">Central Appetite Regulation:<\/b> Crosses blood-brain barrier structures to act directly on the arcuate nucleus and lateral hypothalamus, enhancing anorexigenic pro-opiomelanocortin (POMC) neuronal signaling while inhibiting orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways. This increases satiety, reduces hunger, and decreases food cravings.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"10,1,0\"><b data-path-to-node=\"10,1,0\" data-index-in-node=\"0\">Gastrointestinal Transit:<\/b> Delays early postprandial gastric emptying, prolonging gastric distension and physical fullness.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"10,2,0\"><b data-path-to-node=\"10,2,0\" data-index-in-node=\"0\">Glycaemic and Metabolic Dynamics:<\/b> Stimulates glucose-dependent insulin secretion from pancreatic <span class=\"math-inline\" data-math=\"\\beta\" data-index-in-node=\"97\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord mathnormal\">\u03b2<\/span><\/span><\/span><\/span><\/span>-cells and inhibits glucagon secretion from <span class=\"math-inline\" data-math=\"\\alpha\" data-index-in-node=\"146\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord mathnormal\">\u03b1<\/span><\/span><\/span><\/span><\/span>-cells during elevated plasma glucose levels.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"10,3,0\"><b data-path-to-node=\"10,3,0\" data-index-in-node=\"0\">Cardiovascular Protection:<\/b> Reduces systemic inflammation, improves endothelial function, and lowers systolic blood pressure.<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"11\">The 2.4 mg weekly dose delivers sustained maximal steady-state receptor activation necessary for significant body weight reduction and clinical cardiovascular risk mitigation.<\/p>\n<h2 data-path-to-node=\"12\">3. Approved Clinical Indications and Therapeutic Scope<\/h2>\n<p data-path-to-node=\"13\">Licensing for Wegovy 2.4 mg includes:<\/p>\n<ul data-path-to-node=\"14\">\n<li>\n<p data-path-to-node=\"14,0,0\"><b data-path-to-node=\"14,0,0\" data-index-in-node=\"0\">Chronic Weight Management (Adults):<\/b> Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with:<\/p>\n<ul data-path-to-node=\"14,0,1\">\n<li>\n<p data-path-to-node=\"14,0,1,0,0\">An initial BMI of <span class=\"math-inline\" data-math=\"\\ge 30\\text{ kg\/m}^2\" data-index-in-node=\"18\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">\u2265<\/span><\/span><span class=\"base\"><span class=\"mord\">30<\/span><span class=\"mord\"><span class=\"mord text\">\u00a0kg\/m<\/span><span class=\"msupsub\"><span class=\"vlist-t\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"sizing reset-size6 size3 mtight\"><span class=\"mord mtight\">2<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span> (obesity), or<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"14,0,1,1,0\">An initial BMI of <span class=\"math-inline\" data-math=\"\\ge 27\\text{ kg\/m}^2\\text{ to }&lt; 30\\text{ kg\/m}^2\" data-index-in-node=\"18\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">\u2265<\/span><\/span><span class=\"base\"><span class=\"mord\">27<\/span><span class=\"mord\"><span class=\"mord text\">\u00a0kg\/m<\/span><span class=\"msupsub\"><span class=\"vlist-t\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"sizing reset-size6 size3 mtight\"><span class=\"mord mtight\">2<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><span class=\"mord text\"><span class=\"mord\">\u00a0to\u00a0<\/span><\/span><span class=\"mrel\">&lt;<\/span><\/span><span class=\"base\"><span class=\"mord\">30<\/span><span class=\"mord\"><span class=\"mord text\">\u00a0kg\/m<\/span><span class=\"msupsub\"><span class=\"vlist-t\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"sizing reset-size6 size3 mtight\"><span class=\"mord mtight\">2<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span> (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p data-path-to-node=\"14,1,0\"><b data-path-to-node=\"14,1,0\" data-index-in-node=\"0\">Cardiovascular Risk Reduction:<\/b> Reduction of the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and obesity or overweight.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"14,2,0\"><b data-path-to-node=\"14,2,0\" data-index-in-node=\"0\">Paediatric Weight Management (<span class=\"math-inline\" data-math=\"\\ge 12\" data-index-in-node=\"30\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">\u2265<\/span><\/span><span class=\"base\"><span class=\"mord\">12<\/span><\/span><\/span><\/span><\/span> Years):<\/b> Adjunct to a reduced-calorie diet and increased physical activity in adolescents aged 12 years and older with an initial BMI at or above the 95th percentile for age and sex (obesity).<\/p>\n<\/li>\n<\/ul>\n<p data-path-to-node=\"15\"><i data-path-to-node=\"15\" data-index-in-node=\"0\">Dosing &amp; Escalation Regimen:<\/i> To minimize gastrointestinal intolerance, treatment follows a mandatory 16-week dose-escalation schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, escalating every 4 weeks) reaching the <b data-path-to-node=\"15\" data-index-in-node=\"207\">2.4 mg weekly maintenance dose<\/b> at Week 17.<\/p>\n<h2 data-path-to-node=\"16\">4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n<ul data-path-to-node=\"17\">\n<li>\n<p data-path-to-node=\"17,0,0\"><b data-path-to-node=\"17,0,0\" data-index-in-node=\"0\">Absorption:<\/b> Absolute bioavailability of subcutaneous semaglutide is approximately 89%. Maximum plasma concentration (<span class=\"math-inline\" data-math=\"C_{max}\" data-index-in-node=\"117\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\"><span class=\"mord mathnormal\">C<\/span><span class=\"msupsub\"><span class=\"vlist-t vlist-t2\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"sizing reset-size6 size3 mtight\"><span class=\"mord mtight\"><span class=\"mord mathnormal mtight\">ma<\/span><span class=\"mord mathnormal mtight\">x<\/span><\/span><\/span><\/span><\/span><span class=\"vlist-s\">\u200b<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>) is reached 1 to 3 days (<span class=\"math-inline\" data-math=\"T_{max}\" data-index-in-node=\"150\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\"><span class=\"mord mathnormal\">T<\/span><span class=\"msupsub\"><span class=\"vlist-t vlist-t2\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"sizing reset-size6 size3 mtight\"><span class=\"mord mtight\"><span class=\"mord mathnormal mtight\">ma<\/span><span class=\"mord mathnormal mtight\">x<\/span><\/span><\/span><\/span><\/span><span class=\"vlist-s\">\u200b<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>) post-dose.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,1,0\"><b data-path-to-node=\"17,1,0\" data-index-in-node=\"0\">Distribution:<\/b> Semaglutide is bound extensively to plasma proteins (&gt; 99%, primarily human serum albumin). Steady-state volume of distribution (<span class=\"math-inline\" data-math=\"V_d\" data-index-in-node=\"143\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\"><span class=\"mord mathnormal\">V<\/span><span class=\"msupsub\"><span class=\"vlist-t vlist-t2\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"sizing reset-size6 size3 mtight\"><span class=\"mord mathnormal mtight\">d<\/span><\/span><\/span><\/span><span class=\"vlist-s\">\u200b<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>) is approximately <span class=\"math-inline\" data-math=\"12.5\\text{ L}\" data-index-in-node=\"165\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\">12.5<\/span><span class=\"mord text\"><span class=\"mord\">\u00a0L<\/span><\/span><\/span><\/span><\/span><\/span>.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,2,0\"><b data-path-to-node=\"17,2,0\" data-index-in-node=\"0\">Biotransformation:<\/b> Semaglutide undergoes extensive metabolic degradation via proteolytic cleavage of the peptide backbone and sequential <span class=\"math-inline\" data-math=\"\\beta\" data-index-in-node=\"137\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord mathnormal\">\u03b2<\/span><\/span><\/span><\/span><\/span>-oxidation of the fatty acid side chain. It does not rely on cytochrome P450 (CYP) pathways for clearance.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"17,3,0\"><b data-path-to-node=\"17,3,0\" data-index-in-node=\"0\">Elimination:<\/b> Primary elimination routes are renal and faecal, following breakdown into small peptide components. Clearance is low (<span class=\"math-inline\" data-math=\"\\approx 0.05\\text{ L\/h}\" data-index-in-node=\"131\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">\u2248<\/span><\/span><span class=\"base\"><span class=\"mord\">0.05<\/span><span class=\"mord text\"><span class=\"mord\">\u00a0L\/h<\/span><\/span><\/span><\/span><\/span><\/span>), resulting in an elimination half-life (<span class=\"math-inline\" data-math=\"t_{1\/2}\" data-index-in-node=\"196\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mord\"><span class=\"mord mathnormal\">t<\/span><span class=\"msupsub\"><span class=\"vlist-t vlist-t2\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"sizing reset-size6 size3 mtight\"><span class=\"mord mtight\">1\/2<\/span><\/span><\/span><\/span><span class=\"vlist-s\">\u200b<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>) of approximately 1 week (7 days), enabling once-weekly subcutaneous administration.<\/p>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"18\">5. Physiological Effects and Adverse Event Spectrum<\/h2>\n<p data-path-to-node=\"19\">Semaglutide produces substantial reductions in total body weight (primarily body fat mass), decreases visceral adiposity, lowers fasting and postprandial blood glucose, and reduces systolic blood pressure and inflammatory markers.<\/p>\n<h3 data-path-to-node=\"20\">Adverse Drug Reaction Spectrum<\/h3>\n<ul data-path-to-node=\"21\">\n<li>\n<p data-path-to-node=\"21,0,0\"><b data-path-to-node=\"21,0,0\" data-index-in-node=\"0\">Very Common (<span class=\"math-inline\" data-math=\"\\ge 1\/10\" data-index-in-node=\"13\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">\u2265<\/span><\/span><span class=\"base\"><span class=\"mord\">1\/10<\/span><\/span><\/span><\/span><\/span>):<\/b> Nausea, vomiting, diarrhoea, constipation, abdominal pain, headache, fatigue\/asthenia.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"21,1,0\"><b data-path-to-node=\"21,1,0\" data-index-in-node=\"0\">Common (<span class=\"math-inline\" data-math=\"\\ge 1\/100\" data-index-in-node=\"8\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">\u2265<\/span><\/span><span class=\"base\"><span class=\"mord\">1\/100<\/span><\/span><\/span><\/span><\/span> to <span class=\"math-inline\" data-math=\"&lt;1\/10\" data-index-in-node=\"21\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">&lt;<\/span><\/span><span class=\"base\"><span class=\"mord\">1\/10<\/span><\/span><\/span><\/span><\/span>):<\/b> Dyspepsia, eructation, flatulence, gastro-oesophageal reflux disease, gastritis, abdominal distension, cholelithiasis, dizziness, hair loss (alopecia), injection site reactions.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"21,2,0\"><b data-path-to-node=\"21,2,0\" data-index-in-node=\"0\">Uncommon (<span class=\"math-inline\" data-math=\"\\ge 1\/1,000\" data-index-in-node=\"10\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">\u2265<\/span><\/span><span class=\"base\"><span class=\"mord\">1\/1<\/span><span class=\"mpunct\">,<\/span><span class=\"mord\">000<\/span><\/span><\/span><\/span><\/span> to <span class=\"math-inline\" data-math=\"&lt;1\/100\" data-index-in-node=\"25\"><span class=\"katex\"><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"base\"><span class=\"mrel\">&lt;<\/span><\/span><span class=\"base\"><span class=\"mord\">1\/100<\/span><\/span><\/span><\/span><\/span>):<\/b> Acute pancreatitis, cholecystitis, elevated heart rate, elevated pancreatic enzymes (lipase, amylase), delayed gastric emptying.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"21,3,0\"><b data-path-to-node=\"21,3,0\" data-index-in-node=\"0\">Rare (&lt;1\/1,000):<\/b> Anaphylactic reactions, angioedema, acute kidney injury secondary to dehydration.<\/p>\n<\/li>\n<\/ul>\n<h2 data-path-to-node=\"22\">6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n<h3 data-path-to-node=\"23\">Contra-indicaties<\/h3>\n<ul data-path-to-node=\"24\">\n<li>\n<p data-path-to-node=\"24,0,0\">Personal or family history of Medullary Thyroid Carcinoma (MTC).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"24,1,0\">Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"24,2,0\">Known severe hypersensitivity to semaglutide or any formulation excipients.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"24,3,0\">Pregnancy and breastfeeding (discontinue at least 2 months prior to a planned pregnancy).<\/p>\n<\/li>\n<\/ul>\n<h3 data-path-to-node=\"25\">Key Drug Interactions<\/h3>\n<ul data-path-to-node=\"26\">\n<li>\n<p data-path-to-node=\"26,0,0\"><b data-path-to-node=\"26,0,0\" data-index-in-node=\"0\">Oral Medications:<\/b> Semaglutide-induced delayed gastric emptying can alter the rate and absorption profile of concomitantly administered oral medications. Caution is advised with narrow therapeutic index oral drugs.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"26,1,0\"><b data-path-to-node=\"26,1,0\" data-index-in-node=\"0\">Insulin and Insulin Secretagogues:<\/b> When co-administered with sulfonylureas or insulin in patients with type 2 diabetes, the risk of severe hypoglycaemia is increased; dose reductions of insulin or secretagogues may be required.<\/p>\n<\/li>\n<\/ul>\n<h3 data-path-to-node=\"27\">Clinical Precautions and Monitoring<\/h3>\n<ul data-path-to-node=\"28\">\n<li>\n<p data-path-to-node=\"28,0,0\"><b data-path-to-node=\"28,0,0\" data-index-in-node=\"0\">Acute Pancreatitis:<\/b> Patients should be observed for severe, persistent abdominal pain radiating to the back. If pancreatitis is suspected, semaglutide must be permanently discontinued.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"28,1,0\"><b data-path-to-node=\"28,1,0\" data-index-in-node=\"0\">Gallbladder Disease:<\/b> Rapid weight loss elevates the risk of cholelithiasis and cholecystitis; clinical evaluation is required if biliary symptoms occur.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"28,2,0\"><b data-path-to-node=\"28,2,0\" data-index-in-node=\"0\">Diabetic Retinopathy:<\/b> Rapid improvement in glycaemic control in patients with type 2 diabetes and pre-existing retinopathy has been associated with temporary worsening of diabetic retinopathy.<\/p>\n<\/li>\n<li>\n<p data-path-to-node=\"28,3,0\"><b data-path-to-node=\"28,3,0\" data-index-in-node=\"0\">Renal Function &amp; Dehydration:<\/b> Severe gastrointestinal adverse reactions can cause volume depletion, leading to acute renal failure. Patients must maintain adequate fluid intake.<\/p>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div>","protected":false},"excerpt":{"rendered":"<p data-path-to-node=\"1\">Wegovy 2.4 mg (semaglutide) is a once-weekly long-acting glucagon-like peptide-1 (GLP-1) receptor agonist indicated as the maximum target maintenance dose for chronic weight management and major adverse cardiovascular event (MACE) risk reduction in eligible adult and paediatric patients.<\/p>\n<h3 data-path-to-node=\"3\">\u00a0<\/h3>","protected":false},"featured_media":6975,"comment_status":"closed","ping_status":"closed","template":"","meta":{"postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""}},"product_brand":[],"product_cat":[105],"product_tag":[111,110],"class_list":["post-6974","product","type-product","status-publish","has-post-thumbnail","product_cat-weight-loss","product_tag-semaglutide","product_tag-wegovy-2-4mg","instock","shipping-taxable","purchasable","product-type-simple"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.5 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Wegovy 2.4mg - British Pharmacy<\/title>\n<meta name=\"description\" content=\"Wegovy 2.4mg is a prescription medication designed to help adults struggling with obesity or overweight conditions achieve sustainable weight loss.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bristishpharmacy.co.uk\/nl\/shop\/wegovy-2-4mg\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wegovy 2.4mg\" \/>\n<meta property=\"og:description\" content=\"Wegovy 2.4 mg (semaglutide) is a once-weekly long-acting glucagon-like peptide-1 (GLP-1) receptor agonist indicated as the maximum target maintenance dose for chronic weight management and major adverse cardiovascular event (MACE) risk reduction in eligible adult and paediatric patients.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bristishpharmacy.co.uk\/nl\/shop\/wegovy-2-4mg\/\" \/>\n<meta property=\"og:site_name\" content=\"British Pharmacy\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-16T10:12:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bristishpharmacy.co.uk\/wp-content\/uploads\/2025\/12\/5030779354148965209.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"733\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/wegovy-2-4mg\\\/\",\"url\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/wegovy-2-4mg\\\/\",\"name\":\"Wegovy 2.4mg - British Pharmacy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/wegovy-2-4mg\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/wegovy-2-4mg\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/5030779354148965209.jpg\",\"datePublished\":\"2025-12-10T15:48:56+00:00\",\"dateModified\":\"2026-09-16T10:12:44+00:00\",\"description\":\"Wegovy 2.4mg is a prescription medication designed to help adults struggling with obesity or overweight conditions achieve sustainable weight loss.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/wegovy-2-4mg\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/wegovy-2-4mg\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/wegovy-2-4mg\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/5030779354148965209.jpg\",\"contentUrl\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/5030779354148965209.jpg\",\"width\":960,\"height\":733,\"caption\":\"Wegovy 2.4mg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/wegovy-2-4mg\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shop\",\"item\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/shop\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Wegovy 2.4mg\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/#website\",\"url\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/\",\"name\":\"British Pharmacy\",\"description\":\"Order Medication &amp; Pills Online\",\"publisher\":{\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/#organization\",\"name\":\"British Pharma\",\"url\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Site-icon.png\",\"contentUrl\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Site-icon.png\",\"width\":513,\"height\":513,\"caption\":\"British Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/bristishpharmacy.co.uk\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wegovy 2.4mg - British Pharmacy","description":"Wegovy 2,4 mg is een recept medicatie ontworpen om te helpen de volwassenen kampt met zwaarlijvigheid of overgewicht voorwaarden voor een duurzaam gewichtsverlies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bristishpharmacy.co.uk\/nl\/shop\/wegovy-2-4mg\/","og_locale":"nl_NL","og_type":"article","og_title":"Wegovy 2.4mg","og_description":"Wegovy 2.4 mg (semaglutide) is a once-weekly long-acting glucagon-like peptide-1 (GLP-1) receptor agonist indicated as the maximum target maintenance dose for chronic weight management and major adverse cardiovascular event (MACE) risk reduction in eligible adult and paediatric patients.\u00a0","og_url":"https:\/\/bristishpharmacy.co.uk\/nl\/shop\/wegovy-2-4mg\/","og_site_name":"British Pharmacy","article_modified_time":"2026-09-16T10:12:44+00:00","og_image":[{"width":960,"height":733,"url":"https:\/\/bristishpharmacy.co.uk\/wp-content\/uploads\/2025\/12\/5030779354148965209.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Geschatte leestijd":"3 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bristishpharmacy.co.uk\/shop\/wegovy-2-4mg\/","url":"https:\/\/bristishpharmacy.co.uk\/shop\/wegovy-2-4mg\/","name":"Wegovy 2.4mg - British Pharmacy","isPartOf":{"@id":"https:\/\/bristishpharmacy.co.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bristishpharmacy.co.uk\/shop\/wegovy-2-4mg\/#primaryimage"},"image":{"@id":"https:\/\/bristishpharmacy.co.uk\/shop\/wegovy-2-4mg\/#primaryimage"},"thumbnailUrl":"https:\/\/bristishpharmacy.co.uk\/wp-content\/uploads\/2025\/12\/5030779354148965209.jpg","datePublished":"2025-12-10T15:48:56+00:00","dateModified":"2026-09-16T10:12:44+00:00","description":"Wegovy 2,4 mg is een recept medicatie ontworpen om te helpen de volwassenen kampt met zwaarlijvigheid of overgewicht voorwaarden voor een duurzaam gewichtsverlies.","breadcrumb":{"@id":"https:\/\/bristishpharmacy.co.uk\/shop\/wegovy-2-4mg\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bristishpharmacy.co.uk\/shop\/wegovy-2-4mg\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/bristishpharmacy.co.uk\/shop\/wegovy-2-4mg\/#primaryimage","url":"https:\/\/bristishpharmacy.co.uk\/wp-content\/uploads\/2025\/12\/5030779354148965209.jpg","contentUrl":"https:\/\/bristishpharmacy.co.uk\/wp-content\/uploads\/2025\/12\/5030779354148965209.jpg","width":960,"height":733,"caption":"Wegovy 2.4mg"},{"@type":"BreadcrumbList","@id":"https:\/\/bristishpharmacy.co.uk\/shop\/wegovy-2-4mg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bristishpharmacy.co.uk\/"},{"@type":"ListItem","position":2,"name":"Shop","item":"https:\/\/bristishpharmacy.co.uk\/shop\/"},{"@type":"ListItem","position":3,"name":"Wegovy 2.4mg"}]},{"@type":"WebSite","@id":"https:\/\/bristishpharmacy.co.uk\/#website","url":"https:\/\/bristishpharmacy.co.uk\/","name":"British Pharmacy","description":"Order Medication &amp; Pills Online","publisher":{"@id":"https:\/\/bristishpharmacy.co.uk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bristishpharmacy.co.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/bristishpharmacy.co.uk\/#organization","name":"British Pharma","url":"https:\/\/bristishpharmacy.co.uk\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/bristishpharmacy.co.uk\/#\/schema\/logo\/image\/","url":"https:\/\/bristishpharmacy.co.uk\/wp-content\/uploads\/2026\/09\/Site-icon.png","contentUrl":"https:\/\/bristishpharmacy.co.uk\/wp-content\/uploads\/2026\/09\/Site-icon.png","width":513,"height":513,"caption":"British Pharma"},"image":{"@id":"https:\/\/bristishpharmacy.co.uk\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/product\/6974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/comments?post=6974"}],"version-history":[{"count":5,"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/product\/6974\/revisions"}],"predecessor-version":[{"id":10735,"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/product\/6974\/revisions\/10735"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/media\/6975"}],"wp:attachment":[{"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/media?parent=6974"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/product_brand?post=6974"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/product_cat?post=6974"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/bristishpharmacy.co.uk\/nl\/wp-json\/wp\/v2\/product_tag?post=6974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}